Polynucleotides and PDRN in Aesthetic Medicine: Where the Evidence Ends and the Marketing Begins

Polynucleotides and PDRN became one of the most talked-about topics in aesthetic medicine at precisely the moment patients began to describe their concerns differently. In the past, consultations often centered on a specific wrinkle, a nasolabial fold, or loss of volume. Today, a different request is heard more and more often: “my skin feels thinner,” “my face looks tired,” “I don’t want to change my features — I want my skin quality back.” Against this backdrop, treatments that promise not so much to fill as to support tissue repair have naturally moved into the spotlight.

PDRN stands for polydeoxyribonucleotide — purified fragments of DNA polymers. In medicine, it is studied in the context of wound healing, tissue repair, inflammation, and dermatological use. In aesthetic medicine, PDRN and polynucleotides are most often discussed as injectable treatments for improving skin quality, rather than as classic fillers designed to create volume.

This is why polynucleotides quickly acquired an attractive vocabulary around them: regeneration, repair, skin quality, a subtle alternative to more visible interventions. Some of these claims have a scientific basis. Others sound far more confident than the current level of evidence allows. And this is where it is important not to go to extremes: polynucleotides and PDRN should not be dismissed as “just another trend,” but they should not be presented as a universal procedure that replaces fillers, laser treatments, botulinum toxin, microneedling, surgery, or consistent skin care.

In brief: in aesthetic medicine, polynucleotides and PDRN are used mainly to improve skin quality — hydration, texture, elasticity, recovery after damage, and fine lines. But they are not classic volumizing fillers, and they are not yet a procedure with a fully established evidence base for every claimed indication.

The most honest way to describe them is this: they are a promising area of regenerative and injectable aesthetic medicine, with existing clinical data, practical experience, and plausible biological hypotheses — but they still need better-quality studies, standardized protocols, and more cautious communication with patients. This is especially true where advertising starts promising “cellular rejuvenation,” “skin rebooting,” or results that go beyond what clinical data can currently support.

For the patient, the key question is not whether polynucleotides are “real” or “just marketing.” The more precise question is: for which skin condition, with which product, using which technique, with what expectations, and based on what evidence is this being proposed? This logic helps separate a professional medical conversation from an attractive but overly broad advertising promise.

The topic is also complex because the words “polynucleotides,” “PDRN,” “regeneration,” and “skin quality” mean different things to different people. For a doctor, this may be a discussion about fibroblasts, the extracellular matrix, inflammation, hydration, and repair after injury. For a patient, it may mean hoping to look fresher without changing facial features. For a manufacturer, it is a new product category. For a marketer, it is a powerful story that can easily be turned into a promise of “biological rejuvenation.” All these layers exist at once, which is why the conversation needs to be careful and not oversimplified.

Why have polynucleotides and PDRN become such a prominent topic?

In recent years, aesthetic medicine has gradually shifted away from the idea of “doing more” toward the idea of “looking more natural.” This does not mean fillers or other injectable methods have lost their relevance. On the contrary, they remain important tools when the goal is to restore volume, refine contours, or treat specific anatomical areas. But after years of intensive use of volumizing techniques, both patients and doctors have grown tired of overdone results. This has fueled interest in procedures that are not meant to dramatically change the face, but to gradually improve the condition of the tissues.

In this sense, polynucleotides arrived at a very opportune moment. They fit neatly into the demand for “skin quality” — a concept that is difficult to define in one word but easy to recognize in the mirror. It is when skin looks thinner, drier, less resilient, reflects light less well, and recovers more slowly after irritation or procedures. A person may not want filler, may not be ready for laser treatment, or may not have one specific deep wrinkle — yet still feel that their face looks tired.

This is exactly where there is room for products positioned not as “fillers,” but as a way to support the skin. In professional language, they are often accompanied by terms such as “biorevitalization,” “biostimulation,” “injectable hydration,” and “regenerative injectable therapy.” The problem is that these terms are not always used precisely. Sometimes they describe a real mechanism or clinical rationale; sometimes they simply create a sense of novelty.

Polynucleotides and PDRN are often discussed alongside PRP, PRF, microneedling, lasers, and other procedures also associated with tissue repair and remodeling. For example, the topic of microneedling with PRP and PRF follows a similar logic: not simply “removing a wrinkle,” but using controlled injury or biological material to trigger repair processes. But similar language does not mean the same level of evidence or the same outcome. Each method has its own mechanisms, risks, protocols, and limits.

With polynucleotides, it is especially important not to replace medical precision with an appealing metaphor. When a patient is told that a procedure “restores the skin,” this may mean very different things: improved hydration, fewer fine lines, barrier support, texture refinement, gentle dermal remodeling, or faster recovery after another procedure. But it does not necessarily mean a visible lifting effect, radical rejuvenation, or a result comparable to surgery.

In a publication by Nark-Kyoung Rho, Suneel Chilukuri, Gavin Chan, Michael James Kim, Jihye Shin, and Atchima Suwanchinda, polynucleotides are presented as an area in which clinical data are still accumulating. The authors describe possible mechanisms of action involving hydration, tissue remodeling, and repair, but they do not present the field as a fully standardized method for all patients.

In their publication, Rho and co-authors state plainly: “The current evidence base remains limited.”

This short statement matters just as much as the optimistic conclusions about the method’s potential. It marks the boundary between cautious scientific language and advertising confidence. If a doctor discusses polynucleotides calmly, explains the limitations, and does not promise an instant “minus ten years,” that looks more like a professional approach. If the procedure is presented as a universal replacement for everything that came before it, it is worth asking more questions.

This is also a good place to mention a broader issue in injectable aesthetics. Any new product on the market quickly develops not only a medical biography, but a commercial one. First come the data, then training seminars, then clinical protocols, and then advertising formulas for patients. At every stage, the message may become simplified. That is why, in the topic of the limits of injectable aesthetics, it is important to understand that a method’s capabilities are determined not by how fashionable the term is, but by the quality of evidence, anatomy, technique, and the patient’s realistic request.

There is another reason for their popularity: changing attitudes toward aging. Some patients no longer want to look “different” or “younger at any cost.” They want to look rested, have denser and better-hydrated skin, and cope better with seasonal changes, procedures, stress, weight loss, or hormonal fluctuations. For these requests, polynucleotides sound appealing because they promise not a new face, but better condition of one’s own skin. Psychologically, that is a softer message than “correcting a defect.”

But this softness can also be a trap. When a procedure is described as gentle, natural, and restorative, patients sometimes automatically perceive it as almost risk-free. That is a mistake. Even if the product is not a classic filler and does not create significant volume, it is still injected into tissue. Sterility, technique, skin reactions, contraindications, product quality, and practitioner qualifications all matter. “Not a filler” does not mean “not to be taken seriously.”

This is why polynucleotides are best viewed not as a fashionable procedure name, but as part of a broader conversation about skin quality. If the consultation includes diagnostics, tissue assessment, discussion of alternatives, explanation of the protocol, and realistic limits, the topic becomes medical. If there are only attractive phrases about “genetic repair” or “a new era of rejuvenation,” it starts to look more like selling a trend.

What are these substances, and how might they work in the skin?

Polynucleotides are chains of nucleotides — the structural units of nucleic acids. In the context of aesthetic medicine, this does not mean “implanting foreign DNA” into the skin or changing the genetic code. It refers to biomolecules that may interact with the tissue environment and influence hydration, cellular activity, inflammation, the extracellular matrix, and repair processes.

PDRN is polydeoxyribonucleotide. In simple terms, it consists of purified fragments of DNA polymers derived from biological raw materials and studied as substances with potential regenerative activity. In a medical context, PDRN is associated with wound healing, tissue repair, and anti-inflammatory mechanisms. In aesthetic medicine, it is more often discussed in relation to skin quality, fine lines, texture, and recovery after procedures.

In everyday patient language, these concepts are often blurred: some people say “polynucleotides,” others say “PDRN,” and others say “salmon DNA.” This simplification is understandable, but it is not very useful for medical assessment. Different products may vary in molecular weight, purification, concentration, source, formulation, indications, and method of administration. So the discussion should not be about the “trend” alone, but about a specific product and a specific protocol.

It is often mentioned that the raw material for such products is obtained from purified fragments of fish DNA, including salmon or trout. In advertising language, this sometimes turns into sensational phrasing, but the source itself is neither proof of effectiveness nor a reason to panic. Other factors matter more: degree of purification, quality control, regulatory status, instructions for use, clinical data, and the safety of the specific product.

Scientific publications describe several possible mechanisms for polynucleotides. One is their ability to retain water and create a hydrophilic environment that may support tissue hydration and elasticity. Another is their effect on fibroblasts — the cells involved in synthesizing components of the extracellular matrix. Anti-inflammatory effects, involvement in repair of damaged tissue, possible influence on angiogenesis, and dermal remodeling are also discussed.

It is important not to turn a mechanism into a promise. If a substance is associated with fibroblast activity in laboratory conditions or in individual clinical observations, this does not mean that every patient will achieve a pronounced and predictable anti-aging result after a course of treatments. Biological plausibility is only one level of evidence. Clinical practice requires controlled studies, clear assessment criteria, long-term follow-up, and comparison with alternatives.

In the publication by Rho and co-authors, one proposed mechanism of action for polynucleotides is linked to the formation of a hydrophilic matrix that may support hydration and tissue remodeling. This explains why such products are more logically viewed as skin-quality treatments than as materials for mechanical volume replacement.

This is a fundamental distinction. A hyaluronic acid filler mostly works as a material that adds or restores volume, changes contours, supports tissues, or corrects a fold. It has its own risks, including vascular complications, migration, swelling, nodules, or the need for dissolution. This is why the separate topic of hyaluronidase and safe filler dissolution matters for patients undergoing volumizing injectable treatments.

Polynucleotides should not be perceived as “the same kind of filler, only more natural.” If a product does not create pronounced volume, it will not solve the same problems as volumetric correction. If a patient has significant loss of support in the midface, deep folds, ptosis, or excess skin, polynucleotides may improve the quality of superficial tissues, but they will not replace methods that work with anatomical support.

On the other hand, for some patients, the lack of emphasis on volume is precisely the advantage. A person may fear an “overfilled” face, may not want their features changed, may have thin skin, or may have had a poor experience with injections in the past. In such cases, a method that promises gradual improvement in texture, hydration, and recovery can be appealing. But appeal should not replace proper selection of indications.

Injectable products and cosmetics with PDRN must also be clearly distinguished. This boundary is very important because the cosmetics market quickly adopted the popular term. A serum, cream, or mask with PDRN is not the same as a medical injectable product. Home-care products raise different questions: molecular stability in the formula, penetration through the skin barrier, concentration, storage conditions, and compatibility with other ingredients. Even if an injectable product has promising data, this does not mean that any cream with a bold label claim will have the same effect.

This does not mean cosmetics should be dismissed. Home care can do a lot: support the barrier, reduce dryness, improve comfort, even out tone, reduce irritation, and enhance the results of procedures. But it works on a different level. A product applied to the surface of the skin cannot automatically reproduce the effect of a product injected into tissue. If a brand uses the word PDRN, one should look not only at the name, but also at the formula, concentration, stability, studies of that specific product, and the realism of the manufacturer’s claims.

This is where marketing often works very subtly. It transfers trust from the medical context to the cosmetic one. A patient hears that PDRN is used in regenerative medicine or wound healing and automatically expects a similar effect from a home-care product. But the molecule’s route into the tissues, the dose, the form, and the clinical objective are completely different. So the phrase “contains PDRN” is not, in itself, proof of effectiveness.

The review by Park and co-authors is important because it considers PDRN not as a trendy cosmetic ingredient, but as a substance with regenerative potential in dermatology, particularly in wound healing and tissue repair. For aesthetic medicine, this creates a scientific basis — but it does not turn every procedure or cosmetic product with PDRN into a guaranteed anti-aging method.

Park and co-authors write that PDRN has “regenerative effects in dermatology,” including improvements in skin texture, wrinkle reduction, and faster wound healing.

This quote is useful precisely because it ties PDRN to a medical context, not to an unlimited promise of rejuvenation. If a substance is being studied in dermatology and tissue repair, that creates grounds for aesthetic use. But a basis is not the same as a guaranteed result from any procedure or any cosmetic product carrying that name.

Another difficulty is the difference between “may support” and “guarantees repair.” Scientific texts often use cautious language: potentially, may contribute, preliminary data, further studies are needed. In advertising, these phrases quickly become “restores,” “rejuvenates,” “activates regeneration,” and “repairs the skin.” It is in this translation from scientific caution into commercial certainty that the greatest risk of inflated expectations appears.

So patients are better off remembering a simple rule. If a doctor explains that the product may be part of a program to improve skin quality, talks about a course of treatments, gradual effect, limitations, and alternatives, that sounds realistic. If the procedure is sold as universal regeneration for any age, any skin, and any concern, it looks much more like marketing.

Where is the evidence, and where are we still dealing with cautious expectations?

There is indeed an evidence base for polynucleotides in aesthetic medicine. This is not an empty term that appeared only on social media. There are reviews, clinical studies, and papers on the periorbital area, wrinkles, skin texture, scars, hydration, and tolerability. But the quality and scale of these data do not yet allow us to speak of final standardization.

The most useful type of publication for practical understanding is a systematic review. It does not simply take one successful study; it attempts to collect all available studies according to defined criteria. A systematic review by Smaragda Lampridou, Sian Bassett, Maurizio Cavallini, and George Christopoulos included nine studies with a total of 219 patients treated with polynucleotides. The authors assessed the quality of evidence as low to moderate and noted differences in injection areas, techniques, and procedural characteristics.

In the systematic review, Lampridou and co-authors write: “Nine studies of low and moderate quality were included.”

This is not a negative conclusion. On the contrary, it is quite balanced. The authors do not say the method does not work. They note that polynucleotide injections showed promising results in reducing wrinkles and improving skin texture and elasticity, while adverse reactions were generally mild and temporary. But they also clearly show the limits: few studies, small samples, heterogeneous protocols, different designs, and the need for stronger evidence.

This kind of answer may disappoint those who want a simple “yes” or “no.” But in medicine, it is often the most honest answer. Polynucleotides do not look like an empty trend. However, they also do not look like a procedure about which we can already say: “everything is proven, the protocols are the same, the indications are clear, and the long-term results are well understood.”

The review by Lee and co-authors also supports the idea that this is a promising field. It describes polynucleotides as agents used to improve skin texture, reduce wrinkle depth, and enhance facial appearance. At the same time, the authors emphasize the need for further research to better determine the optimal use, effectiveness, and safety of these products.

Lee and co-authors write that polynucleotides have been used to “improve skin texture, reduce wrinkle depth, and improve appearance.”

For a doctor, this means the need for proper patient selection. For a patient, it means learning how to read advertising correctly. If studies refer to fine lines, skin quality, elasticity, or texture, one should not automatically expect correction of the facial oval, tissue lifting, or replacement of filler in an area of volume deficit. If a publication describes the periorbital area or a certain type of scar, it does not mean the result will be the same on the neck, cheeks, hands, or décolletage.

Why is it so difficult to draw a definitive conclusion? Because studies on polynucleotides often differ from one another not in minor details, but in essential parameters. One study may assess the eye area; another, facial skin overall; a third, scars or the scalp. One may use one product, another a different product. Concentrations, number of sessions, intervals between them, injection technique, injection depth, and outcome criteria all vary. This makes it difficult to take all the data and turn them into one simple universal protocol for practice.

There is also the question of how results are assessed. A patient may say, “my skin looks better.” A doctor may see less dryness, better density, softer texture, and reduced fine lines. But for evidence-based medicine, it matters exactly how this was measured: with scales, photographs, instrumental methods, histology, independent assessment, patient questionnaires, or a combination of these approaches. If different studies measure different parameters, they become harder to compare.

Another nuance is follow-up duration. Many aesthetic procedures can produce early subjective improvement due to swelling, hydration, the very fact of undergoing a treatment course, or changes in skin care. But to assess true tissue remodeling, it is important to look not only at the first few weeks, but at a longer period. This is why long-term data are especially important. They help show how durable the result is and whether the early effect is being overestimated.

A separate issue is comparison with alternatives. Patients need to know not only whether a procedure can produce improvement. They also need to understand whether, for their concern, there is a method with stronger evidence, a more predictable result, or a lower cost. For example, for fine lines and dryness, the answer may include home care, photoprotection, retinoids, barrier-supporting procedures, laser treatments, microneedling, biorevitalization, or combinations. Polynucleotides may be part of this logic, but they should not automatically displace everything else simply because they are new.

Safety is another separate question. In available studies, polynucleotides are often described as well tolerated, with adverse reactions generally mild and temporary: swelling, redness, pain at the injection site, bruising, itching, and short-lived discomfort. In the article by Rho and co-authors, it is noted that at the time of publication, the literature contained no reports of granulomas or vascular occlusion associated with polynucleotides. This is encouraging, but it should not be converted into the statement “there are no risks.”

An injectable procedure always remains an injectable procedure. There are risks related to injection technique, anatomy, sterility, tissue response, product quality, patient condition, comorbidities, and combination with other methods. Even if a product has a favorable tolerability profile, this does not exempt the doctor from assessing the area, medical history, contraindications, and the realism of the patient’s expectations.

It is also important to remember conflicts of interest in some publications. For example, the article by Rho and co-authors states that medical editorial support was funded by PharmaResearch, and that some authors had advisory or employment relationships with the company. This does not mean the publication should be ignored. But it does mean it should be read as an expert perspective with a transparently stated context, not as an independent final verdict.

Overall, the evidence today can be summarized this way: polynucleotides make the most sense where the goal is gradual improvement in skin quality, not a dramatic change in the face. They may be of interest for patients with thin, dry, tired-looking skin, fine lines, reduced elasticity, post-procedure recovery needs, or certain types of scarring. But each of these indications requires individual assessment, because “skin quality” is far too broad a term.

At present, polynucleotides are best justified as an auxiliary tool for improving skin quality, not as a replacement for fillers, botulinum toxin, laser treatments, surgical correction, or treatment of dermatological diseases.

This conclusion is also important because many patients come not with one concern, but with a combination of problems. For example, there may be dryness, fine lines, pigmentation, volume loss, early ptosis, and uneven texture. No single procedure solves everything equally well. Polynucleotides may be part of the plan, but the plan itself should be built from diagnosis, not from the popularity of a product.

Sometimes the correct answer may not be “do polynucleotides,” but first stabilize the skin barrier, adjust home care, address photoprotection, treat a dermatological condition, and only then add injectable procedures. In other cases, polynucleotides may be a useful stage after laser treatment, microneedling, or another intervention when recovery needs support. But these decisions must be made individually.

So the biggest problem is not the products themselves, but how they are sometimes presented. When a method with a promising but not yet fully established evidence base is advertised as a “revolution,” a “new standard of rejuvenation,” or a “procedure without drawbacks,” a gap opens between science and patient expectations. Then even a real, moderate effect may be perceived as a disappointment, because the person was sold not an improvement in skin quality, but an almost fantastical renewal.

Where does marketing begin, and how can patients evaluate an offer?

Marketing does not begin when a clinic talks about a new product. Patients have the right to know about modern methods, and doctors have the right to use new tools if they understand their rationale and limitations. The problem begins when a complex medical topic is replaced with a set of attractive but vague promises.

The phrase “improving skin quality” is perfectly acceptable in itself. But it needs to be explained. What exactly is expected: more hydration, less dryness, better texture, reduced fine lines, faster recovery, less redness, scar improvement? How will this be assessed? After how many weeks? How many sessions are needed? What counts as a good result? What will the procedure not change?

A typical advertising scenario looks like this: a patient sees a promise of “regeneration” and fills in the expectations themselves. They hope the procedure will simultaneously remove fine lines, lift tissues, make the skin glow, replace filler, improve the facial oval, and provide that “just back from vacation” effect. But the doctor’s role is to translate this emotional language into real categories: texture, hydration, elasticity, fine lines, recovery after procedures, barrier condition, tolerability, and time to visible results.

Phrases that sound too broad should raise caution: “complete rejuvenation,” “skin reboot,” “genetic repair,” “filler-like effect without filler,” “suitable for everyone,” “no risks,” “replaces laser,” “works on all signs of aging.” Such wording does not always mean the procedure is bad. But it often means the patient is being sold not a medical service with specific limits, but an emotional image.

A good doctor usually speaks less dramatically, but more precisely. They explain why this particular product may be appropriate, what alternatives exist, which results are realistic, why several sessions are needed, why the effect is not immediate, what reactions may occur after injections, and when another method would be a better choice. In a high-quality consultation, there is always room for the phrase “does not replace.”

Polynucleotides do not replace fillers when volume needs to be restored. They do not replace botulinum toxin when the problem is active facial movement. They do not replace laser treatment or peels when the key concern is pronounced pigmentation or surface renewal. They do not replace surgery when there is excess skin or significant ptosis.

But that does not mean they are unnecessary. On the contrary, within their own area, they may be useful precisely because they do not try to do what other methods were designed for. They can complement a plan, be used in delicate areas, offer an option for patients who do not want volumetric correction, or be chosen where the doctor sees potential for gradual tissue improvement.

Patients should ask their doctor a few simple but very revealing questions. Which exact product will be used? Is it polynucleotides, PDRN, or a combination product? What is its regulatory status in the country? For which indications is it approved or actually used? What experience does the doctor have with this specific product? How many sessions are needed, and at what interval? When should results be expected? What side effects are typical? What happens if the patient does not like the result?

Another important question is why the doctor is recommending this procedure rather than another. If the answer is “because it is the newest,” that is not enough. If the doctor explains that the patient has thin skin, fine lines, reduced hydration, no need for volume, but a clear request for gradual texture improvement, that is a much more meaningful rationale.

It is also worth asking how the procedure fits into the overall plan. Polynucleotides should rarely be the only answer to all age-related changes. They may be combined with home care, photoprotection, retinoids, device-based methods, microneedling, laser procedures, or other injectable approaches. But combinations should not be chaotic. If a patient is offered everything on the clinic menu at once, that is not always a sign of a well-thought-out plan.

Who might find polynucleotides interesting? Most often, patients with dry, thin, dehydrated, or tired-looking skin; fine lines; worsening texture; reduced elasticity; post-procedure recovery needs; or delicate areas where added volume is undesirable. They may also be considered in programs where the emphasis is not on a dramatic change in the face, but on gradual restoration of tissue quality.

Who should not expect too much? Patients who want a quick lifting effect, pronounced filling of folds, cheekbone sculpting, correction of deep anatomical changes, removal of excess skin, or radical rejuvenation in one procedure. In such cases, polynucleotides may improve superficial skin quality, but they will not solve the main problem.

A separate category includes patients who come after a negative experience with fillers and are afraid of any injections. For them, it is not enough simply to say “this is not a filler.” It is important to explain exactly how the product differs, what injection technique is used, whether there will be volume, what reactions are possible, and why the expected result should be different. Without this explanation, even a good procedure may generate mistrust.

There is also the opposite extreme: a patient wants “something natural” and therefore automatically considers polynucleotides safer than all other methods. But in medicine, the word “natural” is not a guarantee. Safety is determined not by the source of the raw material, but by product quality, purification, manufacturing control, method of administration, doctor qualification, and the patient’s condition.

Honest language is essential in the topic of PDRN and polynucleotides. There is no need to frighten the patient, but there is also no need to create the impression that this is a “risk-free injection.” A more realistic statement would be: in available studies, adverse reactions were mostly mild and temporary, serious complications are described rarely, but the procedure still requires medical assessment, sterility, knowledge of anatomy, and proper selection of indications.

From a practical point of view, a patient can evaluate a clinic’s offer using three markers. The first is specificity. Are the product, protocol, number of sessions, expected timeline, and possible reactions named? The second is limits. Is it explained what the procedure will not do? The third is comparison. Are alternatives discussed, or are polynucleotides immediately presented as the best option for everyone?

If there is specificity, limits, and comparison, the consultation looks more professional. If there are only enthusiastic words about regeneration, cellular rejuvenation, and a “new era,” there is no need to refuse automatically — but it is worth asking more questions.

Ultimately, polynucleotides and PDRN should be viewed as a promising but not yet fully standardized area of aesthetic medicine. Their strength lies in their potential to work with skin quality, the subtlety of the result, and the possibility of complementing other methods. Their weakness is that marketing sometimes runs ahead of the evidence, and broad statements about regeneration sound more convincing than the actual clinical data.

The best approach for a patient is not to ask whether polynucleotides “work” in general. It is better to ask differently: do I have the kind of concern for which this method makes sense; is the doctor using a certified product; is the protocol clear; are expectations being overstated; are there alternatives with stronger evidence; have the risks and limits of the result been explained to me?

Then the answer becomes much more honest. Polynucleotides and PDRN are not magical regeneration, and they are not an empty fad. They are a field with a real biological rationale, promising clinical data, and, at the same time, questions that science still needs to answer. It is between these two poles — evidence and marketing — that their place in aesthetic medicine currently lies.